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ABSTRACT
Septic shock, a severe inflammatory state secondary to a bacterial infection with
refractory hypotension and tissue hypoperfusion despite adequate fluid resuscitation, is a
leading cause of mortality in intensive care units worldwide. The mortality rate of septic shock
patients can exceed 40% in the U.S., highlighting the need for more effective therapies.
Anakinra, an inflammatory cytokine inhibitor, has been identified as a potential therapy for
reducing various inflammatory states such as sepsis. Our aim is to evaluate the efficacy of
anakinra in reducing mortality in patients with septic shock. This double-blind, randomized
control trial will compare the 28-day mortality of patients who receive a 72-hour intravenous
infusion of anakinra to a group of patients treated by standard of care alone for septic shock in
an intensive care setting. Our goal is to evaluate if the addition of anakinra to standard sepsis
care will result in a significant mortality reduction in patients with septic shock.
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CHAPTER 1 – INTRODUCTION
1.1 Background
Sepsis persists as a major cause of mortality in intensive care units worldwide.
According to a multicenter randomized trial study published by E. Stevenson et al. in 2014, the
nationwide 28-day mortality rate of hospitalized adult patients with severe sepsis in the U.S.
was 29.2%.1 The study also identified up to 27 million hospitalizations associated with sepsis in
2009 alone. A 2016 international consensus report on sepsis identified patients with sepsis at
critically ill stages marked by hyperlactatemia and hypotension to have mortality rates as high
as 54%.2 Worldwide, there are an estimated 31.4 million cases of sepsis per year, contributing
up to 5.3 million deaths worldwide per year.3 This translates into healthcare costs of billions of
dollars per year in the U.S. alone.4 In 2013, over $23 billion was spent on sepsis care in the
U.S., making it the single most expensive condition treated in U.S. hospitals.5 Readmission
rates following hospitalization for sepsis is also high.6 As compared to common and serious
medical conditions such as acute myocardial infarction, heart failure, COPD and pneumonia,
sepsis is the leading cause of unplanned 30-day readmission and is associated with a longer
mean length of stay than any of the aforementioned conditions.
The high mortality rate and prevalence of sepsis demands a clear and effective approach
to treatment that directly translates into improved patient outcome. Understanding the
inflammatory response involved with any of the stages of sepsis has been a challenge for
healthcare providers as a whole. Numerous research efforts have attempted to shed light into
the complex host response that accompanies sepsis. Physicians have continuously attempted to
design an effective, systemic approach in treating sepsis. Despite these many efforts, sepsis
therapy still remains focused heavily on supportive care without a definitive, directed
treatment.7
5

Previous approaches to the critical care of septic patients have focused on early
initiation of antibiotic therapy to control the underlying infection.8 Studies have found that even
a delay of 6 hours in the initiation of antibiotics can result in increased hospital mortality.8 With
advances in understanding the pathophysiology of sepsis, however, new therapeutic approaches
in targeting the mechanism of the underlying rogue inflammatory response itself have been
introduced, namely the development of novel immunomodulatory agents.
It is in the light of this approach that the role of interleukin-1 has been identified as a
potential target for therapy. In sepsis, the host produces pro-inflammatory cytokines, one of
which is interleukin-1(IL-1).9 Upon activation, IL-1 induces fever, inflammation and
hemodynamic shock.10 While the activation of a cytokine such as IL-1 can be beneficial in the
host defense cascade against an invading organism, an exaggerated inflammatory response can
be equally detrimental to a patient. For example, macrophage activation syndrome(MAS) is a
state where inflammatory cytokines such as IL-1 are overexpressed, leading to a “cytokine
storm” (Figure 1). The main clinical features of MAS include pancytopenia, liver dysfunction,
coagulopathy similar to disseminated intravascular coagulation(DIC), and hyperferritinemia.11
Clinically and pathologically, MAS bears strong similarity to hemophagocytic
lymphohistiocytosis (HLH). In fact, MAS, secondary hemophagocytic lymphohistiocytosis,
and sepsis all share the same mechanism of dysregulated inflammation and may exist along a
common spectrum.12
The acute phase of overwhelming inflammation in MAS can subsequently cause
multiorgan dysfunction syndrome(MODS) – a fatal, sepsis-induced state featuring
pancytopenia, tissue hemophagocytosis, liver dysfunction, coagulopathy, and/or CNS
dysfunction.11 Such multiple organ dysfunction requires intensive care.
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Figure 1. Proinflammatory cytokines, macrophage activation syndrome(MAS) and the cytokine
storm.11
The pathogenesis of this cytokine storm, marked by increased levels of numerous
proinflammatory cytokines including IL-1 and ultimate organ dysfunction is also the hallmark
of sepsis shock, a state of unregulated host response to an infection.13 While understanding the
intricate balance of cytokines in the cytokine storm of MAS is challenging, the recognition of
IL-1 as a major player in the inflammatory cascade supports using the blockade of IL-1
receptors as a therapeutic approach in septic patients.9
Interestingly, in sepsis the host also produces its own anti-inflammatory cytokines, such
as the interleukin-1 receptor antagonist (IL-1Ra) (Figure 2). IL-1Ra’s role is to inhibit the
formation of an IL-1 signaling complex and provide negative regulation to a host’s response to
sepsis.14,15 The balance between the pro-inflammatory cytokine IL-1 and anti-inflammatory
cytokine IL-1Ra is important in the regulated response to an infection. Conversely, an
7

imbalance of IL-1 and IL-1Ra has been implicated as the cause or a severity factor in a number
of diseases. Therefore, targeting IL-1 in the therapy of inflammatory diseases has been a
medical challenge marked by many failures and successes.15

Figure 2. IL-1 receptor complex and signaling. Binding of the IL-1 receptor antagonist to the
IL-1R1(receptor) inhibits IL-1 binding and signal transduction.15

As efforts continue to understand the complicated pathophysiological role of IL-1 in an
inflammatory response, studies have linked gene expression of IL-1 receptors/IL-1 receptor
antagonists to outcome in septic shock.16-18 One example is a meta-analysis by Fang, F. et al
that studied the association between an interleukin-1 receptor antagonist (IL1RN) gene 86-bp
VNTR polymorphism and sepsis.18 In this meta-analysis, researchers discovered that although
IL1RN 86-bp VNTR polymorphism is not associated with sepsis mortality, it is associated with
increased risk of sepsis. While the definitive mechanism of the association is not clearly
understood, it can be reasoned that an elevated production of anti-inflammatory cytokines can
also inadvertently interfere with the host’s natural anti-inflammatory process. Another study by
Zhang, A. et al. quantitatively weighed the association between the polymorphisms of IL-1
genes and sepsis. According to this study, polymorphisms of IL-1A-889, IL-1B + 3954 and IL-
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1RN VNTR showed significant associations with the risk of sepsis.17 Furthermore, a
prospective cohort study by Zapata-Tarres, M. et al. showed an increased prevalence of septic
shock in childhood acute lymphoblastic leukemia patients with IL-1 receptor antagonist
polymorphism (ILrN*1/ILrN*2), again showing the impact of IL-1 related genotype variance
on the outcome of sepsis.19

1.2 Statement of the Problem

Anakinra is a recombinant IL-1 receptor antagonist that is proven to be effective in
reducing various inflammatory states.9,15,20,21 It works by preventing the binding of IL-1a or IL1b to its receptors, effectively blocking the inflammation cascade from propelling further.9
Historically, anakinra has been studied for ameliorating various inflammatory processes such as
RA, gout, Type II diabetes, chronic pericarditis, STEMIs and autoinflammatory syndromes
such as Still’s disease.9,21-23

Figure 3. Timeline of Anakinra Use in Various Inflammatory Processes9
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While anakinra has been shown to be effective in various inflammatory diseases, its
therapeutic role remains unknown. Using the same mechanism as in other inflammatory
diseases, blocking the IL-1 receptor and inhibiting the signal transduction may be useful in
sepsis. In fact, as early as in the late 1980s, studies suggested correlation between elevated IL-1
levels and increased mortality from sepsis. The most notable early human trial using anakinra
as a IL-1 blockade in sepsis was a phase III randomized control trial published in 1997 by Opal
et al.24 In this double-blinded, randomized control trial, the efficacy of anakinra in patients with
severe sepsis was analyzed in comparison with a placebo. According to this study, the 28-day,
all-cause mortality rate was 33.1% in the group of subjects treated with anakinra in addition to
standard therapy, while the mortality rate in the placebo group was 36.4%. Despite the attempt
at a pioneering approach, the researchers concluded a 3.3% difference to be insufficient to
demonstrate a statistically significant reduction in mortality when compared with standard
therapy.24,25
It wasn’t until almost two decades after Opal’s original study that anakinra was
reconsidered as possible treatment for sepsis. In February of 2016, Shakoory et al. published a
reanalysis of Opal’s phase III trial in the journal Critical Care Medicine.26 The objective of the
reanalysis was to reevaluate the efficacy of anakinra in decreasing the 28-day mortality in
septic patients, reanalyzing only those patients with features of macrophage activation
syndrome as a surrogate for a more severe inflammatory septic response. The investigators
discovered that while anakinra did not prove efficacious in Opal’s original trial, regrouping the
study subjects according to presence or absence of features associated with macrophage
activation syndrome did appear to improve sepsis survival outcomes.26

10

The reanalysis indicates that patients with septic shock may benefit from interleukin-1
receptor blockade with anakinra given the overlapping clinical features of MAS and septic
shock.

1.3 Goals and Objectives

In the light of this intriguing finding, a randomized, controlled trial focusing on septic
shock patients may provide insight into the efficacy of anakinra as a therapeutic agent in
critically ill septic patients at high risk of death. Our study is designed to focus specifically on
patients with septic shock – a subgroup of septic patients with not only end organ dysfunction
but also with a dysregulated inflammatory response similar to MAS. We are hopeful that while
earlier studies have not found significant improvement in mortality using anakinra in septic
patients, our more targeted approach to the most critically ill, septic shock patients will provide
a better outcome in reduction of mortality. If effective, this therapy will provide a novel
treatment option for patients with septic shock.

1.4 Hypothesis

We hypothesize that adult patients in septic shock treated with anakinra in addition to
standard of care therapy will have a decreased 28-day mortality rate as compared to patients
treated with standard of care alone.
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1.5 Definitions

Sepsis and Septic Shock
For decades, defining sepsis has been challenging. In 2001, several international critical
care societies convened to define sepsis as a systemic inflammatory process that can be divided
into three stages: sepsis, severe sepsis and septic shock.27 The Sepsis Definitions Conference
defined the three stages as follows: “Sepsis is defined as the presence of infection plus some of
the listed signs and symptoms of sepsis. Severe sepsis is defined as sepsis complicated by organ
dysfunction, and septic shock as severe sepsis with acute circulatory failure characterized by
persistent arterial hypotension unexplained by other causes.”28 Despite this definition, defining
who would have poor outcomes in sepsis remained difficult until the recent publication in 2016
of the Sepsis-3 guidelines.2 According to the new guidelines, the term “severe sepsis” has been
dropped and the systemic inflammatory state to an infection is categorized into sepsis and
septic shock. Sepsis is now defined as “life-threatening organ dysfunction caused by a
dysregulated host response to infection” and septic shock as “a subset of sepsis in which
underlying circulatory and cellular/metabolic abnormalities are profound enough to
substantially increase mortality.”2

SIRS, SOFA and qSOFA – Clinical Criteria for Sepsis
There are two widely used methods in clinically identifying sepsis in patients: the SIRS
(Systemic Inflammatory Response Syndrome) Criteria and the SOFA (Sequential Organ
Failure Assessment) Criteria (Tables 1 and 2). Traditionally, sepsis is defined as 2 or more of
the SIRS Criteria with a source of infection. However, the new Sepsis-3 Guidelines recommend
12

the use of SOFA scoring to define the organ dysfunction of a potentially septic patient due to
higher predictive in-hospital mortality compared to the SIRS criteria. Using SOFA, organ
dysfunction is recognized as an increase in the SOFA score of 2 points or more.2
Quick-SOFA (qSOFA) is a new bedside clinical scoring system of three components: 1)
respiratory rate of 22/min or greater, 2) altered mentation, or 3) systolic blood pressure of 100
mmHg or less.2 The utility of qSOFA lies in its simplicity and the ability to quickly assess
potentially septic patients. However, due to its limitations in both sensitivity and specificity, we
will not be utilizing this scoring system in our study.

Clinical Criteria for Septic Shock
Sepsis-3 guidelines define septic shock as sepsis plus the need for vasopressor therapy
to elevate mean arterial pressure (MAP) to ≥ 65 mmHg and lactate to >2 mmol/L (18 mg/dL)
despite adequate fluid resuscitation (Table 1).2

Table 1. Previous and Revised Sepsis and Septic Shock Definitions29
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Table 2. Sequential [Sepsis-Related] Organ Failure Assessment Score2

Standard of Care (for Septic Shock)
Current standard of care for septic shock in intensive care and emergency care settings
include 1) rapidly treating the underlying infection with broad-spectrum antibiotic therapy
followed by subsequent narrowing of antibiotics to appropriate antimicrobial agents, 2)
hemodynamic support through improving stroke volume and intravascular volume
resuscitation, and 3) the use of vasopressors to counteract vasoplegic shock. However, septic
shock management remains largely variable and is dependent on the severity of the disease and
individual response of the patient. For example, recent studies have shown a more “flexible” or
“conservative” approach to fluid resuscitation rather than an aggressive, universal approach
may be more beneficial to patients in septic shock.7 Practice variation still exists and it is
important to recognize the diversity of the population we intend to treat.7,30,31
14

Mortality Rate

For the purposes of our study, we define mortality rate as the percentage of subjects that
achieve the outcome of death from all causes within 28 days of study enrollment. The
percentage will be calculated by the number of deceased subjects divided by the number of
living subjects at 28 days.
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CHAPTER 2 – REVIEW OF THE LITERATURE
2.1 Introduction
An electronic literature review was conducted using the MeSH database system of
PubMed, Ovid, and Cochrane Review. We used a comprehensive list of combinations of the
key terms: “sepsis”, “septic shock”, “interleukin-1”, “IL-1”, “anakinra”, “mortality”, and “28day mortality”. We included both retrospective and prospective studies as well as metaanalyses, dating back to 1991. Editorials or non-systematic reviews were excluded from our
references. The reason for such expanded retrospective research of literature in time was due to
lack of studies conducted in the use of anakinra for sepsis and to evaluate the evolution of
sepsis treatment.

2.2 Review of empirical studies

Our empirical literature review focused on three things:
1) studies that identified the mortality of sepsis, to highlight the weight of the problem we
wanted to address;
2) research in understanding the mechanism behind sepsis, septic shock and the potential antiinflammatory therapies; and
3) studies using anakinra as therapy.
An abbreviated chart of the main articles discussed will be included at the end of each
section.
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Sepsis and Mortality

As mentioned previously, observed mortality rates from sepsis can exceed 40%. We
looked at three main articles that discussed sepsis-associated mortality rates and the factors that
affected the outcome, if relevant.
The earliest study we reviewed was a meta-analysis of retrospective and prospective
studies published by Friedman et al. in 1998, looking at mortality rates in septic shock patients
between 1958-1997.1 The review focused on changes in mortality in septic shock over time. To
achieve this goal, Friedman and his colleagues reviewed literature from 1958-1997 on the
MEDLINE database and identified 131 studies (99 prospective and 32 retrospective) involving
a total of 10,694 patients. The study reported the overall mortality rate of patients in septic
shock across the 131 studies to be an astonishing 49.7%. The study also noted a decreasing
trend of mortality over the study period, at r = 0.49 with p < 0.05. The study also looked at
variability in mortality according to site of infection and changes in the most common
organisms over time.1
While the study raises significant alarm in the high mortality rate identified, it was
confounded by the lack of consistency among the studies in defining severe sepsis and septic
shock and the varying entry criteria for each study. Also, the researchers did not standardize the
studied population by using a severity score for sepsis, thus were unable to stratify or control
for the severity of the illness which limited their analysis. The analysis included studies with
different designs and different aims, further limiting the internal validity of the study. Finally,
the researchers also did not specify the countries from which the studies were conducted.
In 2014, a more thorough meta-analysis was published by Stevenson, E et al., reviewing
36 sepsis trials from 1993-2009.2 The study was conducted in response to an observation that
19

there appeared to be a declining sepsis mortality, leading researchers to question whether the
decline was due to advances in practices or merely a mirage reflecting changes in classification
of patients with “severe sepsis”. The new classification could have possibly led to the inclusion
of less critically ill patients in its definition and therefore falsely reflecting better outcomes. In
this meta-analysis, researchers reviewed 36 multi-centered, randomized prospective trials that
included a total of 14,418 adult (>18 years old) participants with severe sepsis or septic shock
in hospitals across the U.S and abroad. Single-center trials were excluded to reduce bias from
center-specific outcomes. The primary outcome explored in this study was 28-day all-cause
mortality, as planned in our study. The nearly two-decade span of data showed a mortality rate
of 29-46.9%, with a decreasing trend over time consisting of a 3.0% drop annually (95% CI,
0.8%–5.0%; p = 0.009). The average 28-day mortality rate across all trials was 33.2%. The
researchers also calculated standardized mortality ratios for each trial using observed and
predicted mortality rates to identify whether discrepancies existed from differing sepsis
identification criteria. The study showed decline in mortality ratio over time, confirming the
decrease in mortality rates. They also observed a similar trend among trials using different
sepsis identification criteria, suggesting the downtrend in mortality rate was not a result of the
simple re-classification of patients.
While the analysis was useful in reviewing mortality rates and trends leading up to
2009, the study had its limitations in reflecting true mortality rates in severe sepsis/septic
shock. Due to the nature of a meta-analysis, data regarding potential confounders at individual
patient-by-patient level were unavailable and thus unadjusted for. Also, although the multinational, multi-centered trials allowed for larger sample sizes, the results are vulnerable to
internal validity due to variability in practices between different nations. Furthermore, the large
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number of participants may falsely represent statistically significant results while being
exposed to a greater number of confounding biases that are not controlled for. Nonetheless,
Stevenson et al.’s study draws attention to the high mortality rate associated with sepsis
worldwide and despite the downtrend at the turn of the century, it shows that mortality rates in
critically-ill septic patients remains high.
Most recently, in 2016, Fleischmann, C. and his colleagues made another attempt at
evaluating global mortality rates in septic patients.3 In this systematic review, researchers
investigated the incidence and the mortality rate of sepsis and severe sepsis between 19792015, using 15 international citation databases in an attempt to assess the global burden of
sepsis. They searched any relevant literature on sepsis that reported evidence-based
epidemiologic data within a given time frame but excluded studies that were limited to
subgroups of sepsis or certain patient populations such as cancer patients or pediatric patients.
Ultimately the study included 27 international sepsis trials from 18 different countries.
According to their study, the global population incidence for in-hospital sepsis cases was
estimated to be 288 per 100,000 person-years. Individually, the studies reviewed showed sepsis
incidence ranging from 73.6 per 100,000 inhabitants in the United States (1979) to 1,180 per
100,000 inhabitants in Australia (2007–2008). When limiting the data to more recent years
(2003–2015) the study revealed an even higher incidence at 437 per 100,000 person-years. For
in-hospital severe sepsis cases, including septic shock, the investigators reported an incidence
of 148 per 100,000 person-years. During the last decade, the incidence rate for severe sepsis
was 270 per 100,000 person-years. The investigators used 95% confidence intervals for their
analysis with t=0.55-0.99.
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28-day in-hospital mortality rates from sepsis showed great variability between studies,
ranging from 5% to 42.5%, to an estimate of 21% worldwide. For severe sepsis, the estimated
worldwide mortality rate was higher at 28%. Only looking at 2003-2015, the analysis showed a
slightly decreased 28-day mortality rate of 17% in sepsis and 29% in severe sepsis.
The investigators in this study recalculated the population-level incidence rates from
each study using the number of hospital sepsis cases provided in each study and census data
reported for the time of that study. This reduced the variability in reported rates from different
calculation methods in the original studies. However, the wide range of t values (0.55-0.99)
shows the great difference in rates between studies as original publications were of different
populations in different countries. While it may be impossible to control for the variables
between studies from different countries, patient populations and practices, we also note that
the great range in incidence and mortality rates may also reflect the heterogeneity of
identification of sepsis cases among administrations. Achieving a consensus on defining sepsis
has been an ongoing challenge and the difference in definition criteria for sepsis and severe
sepsis among coding systems make global epidemiologic assessment challenging.
The most prominent limitation of this study lies in the fact that only 18 higher-income
countries were included in the study due to lack of sufficient sepsis data from lower-income
countries, limiting its predictive value as a true assessment of sepsis cases worldwide. We can
assume sepsis incidence and mortality rates may be higher in lower-income countries, if we
assume these countries also suffer from higher prevalence of infectious diseases and less
efficient infection control.
While the studies by Friedman, Stevenson, and Fleischmann each showed its own
strengths and weaknesses, they all showed an alarmingly high mortality among the populations
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studied. Despite the declining hospital mortality rates shown in the study by Stevenson, E. et
al., the study by Fleischmann demonstrated the continuing burden of sepsis worldwide,
encouraging the need for continued research in treatment for sepsis.2,3
Date of Study Author
1998 Friedmann, G

Type of Study
Meta-analysis

2014 Stevenson, E

Meta-analysis

2016 Fleischmann, C Meta-analysis

Study Population
Primary Outcome
131 studies (99 prospective, 32
overall mortality
retrospective) involving a total of
10,694 patients
36 sepsis trials globally from 1993- 28-day mortality
2009, total of 14,418 participants
with severe sepsis and septic shock

Study Results
Overall mortality rate 49.7%

Observed mortality rate between
1993-2009: 29-46.9%, ave. 33.2%

27 international sepsis trials from incidence and in- Incidence, mortality rate for:
1979-2015 in 18 countries, total of hospital mortality sepsis - 437 per 100,000 person>2.8 million sepsis cases
years, 17%; severe sepsis -270 per
100,000 person-years, 29%(20032015)

Table 3. Sepsis Mortality in Literature

Inflammatory Cascade and Anti-inflammatory Agents in Sepsis Treatment
While the previous studies mentioned exposed the high disease burden of sepsis, the
next group of studies supports our understanding of the physiologic mechanism that lies behind
the high mortality of sepsis as well as the use of anti-inflammatory agents as treatment.
In 1991, Charles A. Dinarello published an article discussing the role of
proinflammatory cytokines in treatment of septic shock.4 The article focused mainly on two
cytokines, interleukin-1(IL-1) and tumor necrosis factor(TNF). In his article, Dinarello argued
that treating septic shock by either blocking the endotoxins secreted by the causative organisms
or by neutralizing the antibodies was not an effective method. He suggested the direct
inhibition of IL-1 or TNF would be a possible treatment strategy for sepsis by blocking the
inflammation process and therefore a potential solution to reducing the high mortality
associated with septic shock. He supported his argument by proving that an endogenous IL-1
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receptor antagonist blocks shock and death due to Escherichia coli as well as its efficacy in
treating a variety of inflammatory diseases.
Three years later, Charles Natanson presented a study at the 1994 NIH Conference
highlighting the limitations of the new approach to sepsis therapy. In this study, Natanson
analyzed preclinical and clinical trial data of antiendotoxin antibodies and anti-cytokine
therapies for sepsis. The 10 clinical trials discussed in this study did not produce conclusive
results to establish the safety or benefit of using antiendotoxin antibodies or anti-cytokines in
septic shock.5 Natanson noted that although IL-1 inhibition studies have shown some benefit in
animal models, it has not shown clear improvement in human trials. He also discussed the
limitations of searching for a therapy when the exact mechanism of the inflammatory response
is yet poorly understood. While inhibiting the host inflammatory response may be a premise for
new therapy, the complexity of the mechanism in which the cytokines function greatly limits
identifying a successful target for therapy.
Date of Study Author
1991, 1993

Dinarello, C

1994

Natanson, C.

Study Results
Review of the role of IL-1 in septic shock and its
blockade
Review of potential therapies for septic shock using IL-1
inhibition

Table 4. Literature on IL-1 Blockade

Anakinra as Therapy
Anakinra, a recombinant interleukin-1 receptor antagonist, has been most popularly
used in treating chronic inflammatory diseases such as rheumatoid arthritis.6,7 As such, there
have not been many studies conducted which focus on anakinra as a therapy for sepsis. The
most notable study that introduced anakinra as a potential new treatment was a randomized,
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double-blind, confirmatory phase III trial published in July 1997 by Steven Opal.8 In this study,
Opal and his colleagues designed a placebo-controlled, phase III clinical trial studying the
association between sepsis mortality and use of anakinra as therapy. This study was modeled
after an earlier phase III trial by Charles Fischer and Opal9 published four years earlier that
tested two different doses of anakinra in septic patients versus placebo. The initial study did not
show a significant reduction in mortality (28day, all-cause mortality was 34% (102/302) in the
placebo group, 31% (91/298) in the 1.0 mg/kg/hr rhIL-1ra group, and 29% (86/293) in the 2.0
mg/kg/hr rhIL-1ra treated group (p = .23)), however the researchers retrospectively discovered
that the most critically ill patients enrolled in their study had slightly favorable survival benefit
with anakinra.
In the confirmatory study performed in 1994, the researchers recruited 906 patients with
sepsis and/or septic shock from across 91 ICUs in North America and Europe. The patients
were randomized to either receive anakinra 100 mg bolus + 72-hr infusion at 2 mg/kg/hr in
addition to standard therapy or standard therapy alone (placebo). The primary outcome
assessed was all-cause 28-day mortality. Although the study was originally designed to recruit
1,300 patients, the researchers set an interim analysis to be performed when approximately half
of the target population had been enrolled and had completed the trial. When this interim
analysis was performed, the study had recruited 906 patients that met the inclusion criteria.
Complete data was available for assessment of 696 patients. According to the interim analysis,
the 28-day, all-cause mortality rate was 33.1%(116/350) in the anakinra treatment group, while
the mortality rate in the placebo group was 36.4% (126/346), yielding a 9% reduction in
mortality rate (p = .36). With these results, researchers concluded the intervention failed to

25

demonstrate a statistically significant reduction in mortality when compared with standard
therapy.
Although the data failed to show marked reduction in mortality as predicted, the study
was well designed in that it was performed in a large cohort from multiple medical centers in
various countries. There were a total of 11 participating countries with no single center
contributing more than 4% of the entire patient population in the study, strengthening the
generalizability of the study. Nonetheless, a multi-national, multi-centered clinical trials also
has its limitations such as the variability between centers in clinical practice, treatment
protocol, prevalent pathogens and disease recognition and reporting patterns. The study was
also double-blinded to reduce observer bias. However, the researchers reported they may have
been susceptible to bias in favor of a good outcome due to the favorable results published in the
earlier trials. Another confounding factor of the poor results may be due to the improvements in
sepsis care mortality itself, due to advances in disease management. Continuous improvements
have been made in managing critically ill patients with septic shock that may diminish the
room to make improvements in the clinical care of this population.
In summary, Opal and his colleagues concluded the phase III trial of anakinra use in the
treatment of septic patients to be unsuccessful in demonstrating a benefit to continue the trial.
They suggested the need for additional studies to understand the activity of IL-1ra as well as
more studies that target a well-controlled specific population within septic patients to observe a
direct therapeutic benefit.
In the following years, anakinra stayed mainly as a therapy option for inflammatory
states such as RA, gout, diabetes, chronic pericarditis, and autoinflammatory syndromes as well
as MAS. Most clinical studies have been focused in these disease states as briefly outlined
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below. Of note, all studies involving anakinra report little to no adverse side effects of anakinra.
2-7

In one study, 31% of the anakinra-treated patients developed transient injection site reaction

that responded to oral diphenhydramine and local hydrocortisone.10
Among the more recent studies in the last decade, an article was published in Nature
Reviews Rheumatology in 2008, of a 13-year-old girl with systemic juvenile idiopathic arthritis
complicated by macrophage activation syndrome was successfully treated with anakinra.11 Also
in 2011, Nigrovic, PA7 studied the efficacy of anakinra as first-line therapy for systemic
juvenile idiopathic arthritis(JIA) and found rapid resolution of systemic symptoms and
prevention of refractory arthritis in nearly 90% of their study subjects. This study helped
transition the use of anakinra as first-line therapy in systemic JIA from a novel rescue. Later
that year in August, Miettunen, PM et al12 reported a case series of 12 patients in which they
reported resolution of severe pediatric rheumatic disease-associated macrophage activation
syndrome with the added use of anakinra with conventional immunosuppressive therapy.
Following the successful treatment, they concluded the early use of anakinra, used in
conjunction with conventional immunosuppressive therapy, is effective in severe MAS.
Additionally, in 2014, a retrospective review of eight patients with suspected secondary HLH
(hemophagocytic lymphohistiocytosis), an inflammatory response with similar features to
sepsis, in the PICU at Helen DeVos Children’s Hospital in Michigan which showed positive
results in decreasing the systemic inflammation with anakinra use.13 Most recently in 2015, a
retrospective review by Jain, S10 evaluated 13 cases of treatment-refractory recurrent
pericarditis treated with anakinra and found that all 13 patients experienced partial to complete
resolution of symptoms, suggesting anakinra as an effective alternative agent for the
management of glucocorticoid-dependent recurrent pericarditis.
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As such, while anakinra has shown to be effective in various inflammatory diseases
through functional IL-1 receptor blockade as evidenced in the previously mentioned
experimental trials and case reviews, its uses in sepsis has remained limited. To date, the most
cited and valued clinical study investigating the value of rhIL-1RA as therapeutic option in
patients with sepsis remains to be Opal’s study in the early 1990s, although the disappointing
results failing to show a significant reduction in mortality had discouraged the utility of
anakinra in sepsis management.
However, a recent reanalysis published in 2016 by Bita Shakoory14 suggests otherwise.
In this reanalysis study, the patients from Opal’s confirmatory phase III trial were regrouped
based on the features of macrophage activation syndrome(MAS) – patients with hepatobiliary
dysfunction(HBD) and disseminated intravascular coagulation(DIC) were grouped together
while those without the two clinical signs of MAS comprised the control group. Patients were
determined to have HBD if they showed presence of ≥2 of the following: prolonged
prothrombin time (PT), elevated blood levels of aspartate or alanine aminotransferase and/or
serum bilirubin levels above 2.5 mg/dL. DIC was defined as abnormal platelet counts with
prolonged PT or partial thromboplastin time (PTT) in participants without anticoagulation or
other pre-existing factors affecting anticoagulation. Following the regrouping of patients, the
authors of the reanalysis discovered that while the 28-day survival rate remained statistically
non-significant in the non-hepatobiliary dysfunction/disseminated intravascular coagulation
patients (71.4% in anakinra treatment group vs. 70.8% in the control group), the 28-day
survival rate in the hepatobiliary dysfunction/disseminated intravascular coagulation group was
65.4% (anakinra) vs. 35.5% (control). The significant improvement in the mortality rate in the
reanalysis study revisited anakinra as a potential therapeutic agent in patients with septic shock
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and highlighted the need for a second evaluation of a specific subgroup of these patients for the
advantages of IL-1Ra treatment.
Despite the promising results, this study was not without limitations. Since it was a
reanalysis of a previous trial, the study had no control over assigning equal number of patients
to each study arms. Although 763 patients from the original study were included in the
reanalysis, the majority of the cases presented only with DIC or MBD and not both. Only 43
patients had both DIC and HBD, 26 of which were treated with anakinra, leaving 17 in the
placebo arm and creating an underpowered study. Nevertheless, the study results suggested a
targeted population, more specifically patients with septic shock, may benefit from interleukin1 receptor blockade with anakinra.
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Date of Study Author

Type of Study Study Population Intervention

1994

Opal, SM

Phase III,
Randomized
Control Trial

1997

Opal, SM

Phase III,
Randomized
Control Trial

2008

Kelly

Case Report

2011

2011

2014

2015

2016

Primary Outcome Study Results

893 patients with anakinra 100mg bolus at 2mg/kg/hr, 28-day, all-cause 28day, all-cause
sepsis
1mg/kg/hr, placebo
mortality
mortality was 34%
(102/302) in the placebo
group, 31% (91/298) in
the 1.0 mg/kg/hr rhIL1ra group, and 29%
(86/293) in the 2.0
mg/kg/hr rhIL-1ra
treated group (p = .23)
91 ICUs in North anakinra 100mg bolus + 72-hr
28-day, all-cause 33.1% (116/350) in the
America and
infusion at 2mg/kg/hr
mortality
rhIL-1ra treatment
Europe, 906
group, while the
patients with
mortality rate in the
sepsis/septic
placebo group was
shock
36.4% (126/346), yielding
a 9% reduction in
mortality rate (p = .36).
Mortality rate 36% in
placebo group vs. 33% in
patients receiving IL-1ra

13 year-old
female with
systemic juvenile
idiopathic
arthritis(sJIA) and
features of MAS
Nigrovic
Systematic
46 patients with
Review
systemic JIA from
4 countries
Miettunen Case Series
12 pediatric
rheumatic
diseaseassociated MAS
patients
Rajasekaran Retrospective 8 pediatric
Case Series
patients with
secondary
hemophagocytic
lymphohistiocyto
sis(HLH)
Jain
Systematic
13 cases of
Review
treatmentrefractory
recurrent
pericarditis
Shakoory
Re-analysis of 763 patients with
phase III trial sepsis/septic
by Opal
shock, grouped
by hepatobiliary
dysfunction
and/or
disseminated
intravascular
coagulation

Significance
Did not show
significant reduction in
mortality, but
retrospective analysis
showed favorable
trend in critically ill
subgroup

The study was
terminated after an
interim analysis found
that it was unlikely that
the primary efficacy
end points would be
met

anakinra 1mg/kg SQ daily in addition N/A
to standard prednisolone and
ciclosporin therapy

Significant improvement Showed potential for
in symptoms
anakinra use in therapy
for sJIA complicated by
MAS

anakinra +/- corticosteroids or
other DMARDs

Partial to full resolution
of symptoms in >95% of
patients
All patients achieved
MAS remission after
addition of anakinra
within a median of 13
(range 2–19) days
Decline in inflammatory
markers after anakinra
use

Proposed anakinra as
an effective first-line
therapy for sJIA
Showed effectiveness
of anakinra in severe
MAS

all 13 patients
experienced partial to
complete resolution of
symptoms

Proposed anakinra as
an effective alternative
agent for treatment
refractory pericarditis

N/A

anakinra 2mg/kg/day(max 100mg) in N/A
addition to pre-existing MAS
therapy

anakinra at variable doses +/- IVIG
or corticosteroids

N/A

anakinra at various doses after
N/A
refractory to NSAIDs, colchicine and
prednisone for >6mo.

anakinra 100mg bolus at 2mg/kg/hr, 28-day, all-cause 28-day survival rate in
1mg/kg/hr, placebo
mortality
the HBD + DIC group was
65.4%(anakinra) vs.
35.5%(control)

Table 5. Use of Anakinra in Literature
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Showed therapeutic
potential for HLH,
which has similar
clinical features as
sepsis

Revisited anakinra as a
potential therapeutic
agent in patients with
septic shock

2.3 Confounding Variables in Literature
In Opal’s original study the 28-day all-cause mortality rate did not differ significantly
between treatment groups by the site/source of infection, type of pathogen, presence of organ
dysfunction at the time of study entry or the predicted mortality at the time of study entry,
eliminating many of our confounding variables.8 However, given that the study was conducted
decades earlier, we looked for additional literature on possible confounding variables.

Infection Control

Sepsis starts with an infection in the host and the variability of the infectious source or
pathogen itself, may be a confounding factor in a study. One of the major concerns is the effect
of infection source control (i.e. eradicating or hindering the infectious organism) on the
outcome of sepsis. Current guidelines recommend intervention for source control within hours
after diagnosis.
Most recently, in 2017, a Spanish multi-center, prospective observational study of 99
ICUs published by Martinez, M. et al15 attempted to determine the impact source control and its
timing in the management of sepsis. The study enrolled 3,663 patients with severe sepsis or
septic shock during three 4-month periods between 2011 and 2013. A total of 1,173 patients
(32%) underwent source control and compared with patients who did not require source
control, patients who underwent source control had greater prevalence of shock, major organ
dysfunction, bacteremia, inflammatory markers, and lactic acidemia. Also, resuscitation
compliance was worse. However, both hospital mortality and crude ICU mortality was lower in
the source control group, leaving mixed conclusions on whether timely source control directly
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affects sepsis mortality. One of the reasons of these mixed results can be attributed to the
heterogeneity of the process of source control. Rather than a simple antibiotic therapy, proper
source control is a multidisciplinary team effort that is linked to the management of a septic
patient.16
Another previous study reported comprehensive data on infection in sepsis. Gotts, et
al17 published in 2016 an extensive review of 14,000 adult patients in 1265 ICUs from 75
countries on a single day in May 2007. The researchers included demographic, physiological,
bacteriological, therapeutic and outcome data in their analysis to better understand sepsis. Of
7,000 patients identified with an infection, the most common site of infection was the lungs
(64%). The most common isolated organism were Gram negative organisms such Pseudomonas
spp. (20%) and Escherichia coli (16%). While the study does not specify the direct correlation
between variables of infection and mortality, it can be supposed that the variables surrounding
the infection itself can be a source of challenge in standardizing clinical trials.

Demographics
Both Opal’s study and Shakoory’s reanalysis stratified their data by gender and age and
both studies noted that there was no significant difference in mortality by these categories.
However, a review article published recently by Gotts, J. et al17 invites some skepticism. Gotts
and his colleagues report that while women have lower incidence of sepsis than men, the effect
of gender on mortality rate was unclear. The researchers suggested the difference may be
attributed to sex hormones and its effects on immunity as well as possible differences in
cardiovascular physiology and response to infection.17,18 The study by Gotts also noted that
patients are more susceptible to sepsis with increased age.17 The increased risk of sepsis can be
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attributed to the elderly population having more comorbid conditions or generally less
physiological capacity to fight off an infection. However, a multivariate analysis adjusting for
comorbid conditions still showed that patients aged 65 or more with sepsis were 2.3 times more
likely to die.17

Immunosuppression

Since the etiology of sepsis involves an initial infection, any causes of
immunosuppression are risk factors for sepsis17,19,20. A multi-centered, prospective
observational study conducted between 1997-2011 in French ICUs that in patients with severe
sepsis or septic shock concomitant with immunodeficiency had increased risk of mortatlity.21 In
the analysis of 1,981 patients, the 28-day mortality was 31.3% in the immunocompromised
group compared to 28.8% in the immunocompetent group(P=0.26). The conditions identified in
the study to have association with increased mortality were AIDS, non-neutropenic solid tumor,
nonneutropenic hematologic malignancies and all-cause neutropenia.21

The Obesity Paradox

While obesity is considered a risk factor of many chronic diseases, the association
between obesity and mortality in sepsis has been mixed. While some studies show no
association between obesity and mortality, other studies have shown either a positive or
negative correlation with increased mortality.22 In a systematic review of the association
between obesity and in-hospital mortality among septic patients, Trivedi, V et al identified
three studies that reported no significant association between obesity and mortality as well as
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one study that showed increased mortality. The analysis also identified three studies where
mortality among obese patients were lower than other counterparts.22 While there are many
factors that may contribute to variability in sepsis care in obese patients such as underlying
comorbidities, fluid resuscitation, ventilation requirements or antibiotic administration, the
paradoxical findings of decreased mortality in obese patients with sepsis may be associated
with physiological differences in the capacity to respond to an acute inflammatory state.22

Inter-/Intra-facility Transfer

Studies have shown increased risk of mortality in septic patients that are subject to
inter- or intra-facility transfers, most presumably attributed to the delay of early sepsis care.23,24
In a 1998 single-centered retrospective cohort study of 41 patients with septic shock, Lundberg,
J and his colleagues compared the mortality between general ward and ICU setting care. The
study found increased odds ratio of death for ward patients compared to ICU patients (3.57)
and a delay of fluid administration and inotropic support in patients that developed septic shock
in a ward setting.23 The delay in sepsis management for inter-facility transferred patients was
confirmed in a more recent study published in 2015 by Faine, B et al.24 Also a single-center
retrospective cohort study, this study reviewed 193 patients with severe sepsis and septic shock
treated between 2009-2014. The patients were identified by whether they had been transferred
from another local hospital or if they presented to the admitting facility directly through the
emergency department. The results of the study showed that with similar illness severity, interhospital transferred patients were less likely to have received fluid resuscitation by 3 hours of
care (54% vs 89%, p<0.001). However, the study did not find significant differences in the
length of stay in the ICU or mortality.24
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2.4 Review of relevant methodology

Study Design

Our goal was to design a study largely based on the based on the phase III trial of
anakinra in sepsis by Opal et al.8,14 However, as suggested in Shakoory’s reanalysis, we
decided to target patients in a more critical stage of sepsis – septic shock, to evaluate the
efficacy of anakinra in this targeted population. Opal and his colleagues designed a
multicentered, double-blind, randomized control trial of reviewing all-cause 28-day mortality in
sepsis upon which we modeled our study.8 While a multicentered trial would provide better
generalizability as well as better chance of recruiting a large sample size, we decided to design
a single-center trial to eliminate center-specific variability in practices. Also, we deemed that
based on the estimated incidence of septic shock at YNHH, we were confident we would be
able to reach our sample size goal of 394 patients within the two-year timeframe of this study.
To achieve the goal of assessing the efficacy of an intervention (anakinra) in a clinical trial, we
determined a prospective experimental design would be necessary as in Opal’s study. Thus, we
propose a randomized, placebo-controlled clinical trial that allows for evaluation of the cause
and effect of our intervention.

Inclusion and Exclusion Criteria (Sepsis-3 definition, SOFA, qSOFA)

The inclusion and exclusion criteria for our proposed study is similar to the criteria used
in Opal’s confirmatory phase III trial8 (See Appendices I & III). However, we revised the
inclusion criteria to include the most recent definition for sepsis and septic shock to better
match our target population. The entry criteria for our study utilizes the SOFA scoring system
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as well as the current revised definition of septic shock according to the Sepsis-3 consensus
discussed in Chapter 1.25
In our proposed study, we will be following the new Sepsis-3 Guidelines
recommendation to use the SOFA scoring system to define the organ dysfunction of a
potentially septic patient. Based on these guidelines, the authors recommended use of SOFA
scoring to define sepsis, where organ dysfunction is recognized as an increase in the SOFA
score of 2 points or more, which we will use in our study. While we will not be using qSOFA
scores in our screening of patients, the following figure (Figure 3) depicts a proposed clinical
decision-making algorithm for evaluating patients for sepsis or septic shock.

Figure 4. Operationalization of Clinical Criteria Identifying Patients with Sepsis and Septic
Shock25
Additionally, according to the consensus, the clinical criteria for septic shock is defined
as sepsis requiring vasopressor therapy to elevate MAP ≥ 65mmHg AND lactate >2 mmol/L(18
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mg/dL) despite adequate fluid resuscitation. This was based on the finding that the riskadjusted hospital mortality was significantly higher in patients with fluid-resistant hypotension
requiring vasopressors and hyperlactatemia (42.3% for serum lactate level of >2 mmol/L)
compared with either hyperlactatemia or hypertension alone.25

Randomization/Sampling/Blinding Techniques
In Opal’s study, randomization was performed by a computer-generated process. All
principal investigators involved in the study were blinded to the results of the study.8 The
intervention was kept blinded by keeping anakinra and placebo in identical packages prepared
by the manufacturer.8
Also, in another placebo-controlled, randomized, double-blind, parallel-group trial by
Annane, D et al, randomization was performed through a concealed, computer-generated
random number table. To blind the investigators of the assignment, pharmacists utilized
sequentially numbered boxes containing the randomized treatment according to the generated
list, which was confidentially delivered to the investigators.26
In our study, all patients, family members, medical/pharmacy staff and related
investigators will remain blinded throughout the study period utilizing similar randomization
and blinding techniques as the two studies mentioned above.

Primary Outcome Measures and End Points
Opal’s study used 28-day mortality as well as the reanalysis by Shakoory.8,14 While
some other studies have looked at overall mortality, studies such as Annane, D et al.26 studying
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the effects of anakinra used the 28-day survival or mortality as their end point. Also, we based
the mortality of our control group on the mortality rate reported by Stevenson et al.2 which used
28-day mortality as well.2
To decrease variability in length of stay and thus an overestimate or underestimate of
mortality, we propose a 28-day mortality to observe a direct effect of anakinra therapy.

Sample Size
Opal and Fischer’s first phase III trial calculated the sample size needed to be 300
patients per treatment group to detect a 35% reduction in 28-day all-cause mortality with 91%
power at P=0.05. The calculation assumed the placebo mortality rate would be 40%.9
The study was designed to enroll 1,300 patients but the study was terminated after an
interim analysis at which point approximately half of the target population had completed the
trial. Thus, their study power calculation was limited (power 1%).8
The proposed study will aim to have an effect size similar to the original phase III trial
by Fischer and Opal. However, given our study limitations of shorter time to conduct the study
and smaller sample size, we will use a power of 80% with an alpha of 5% to calculate the
sample size of this study. The assumed 28-day mortality for the intervention (anakinra) group is
33.1% as reported by the confirmatory analysis by Opal.8 As for the control group, we
determined the reported by Stevenson et al better reflected the target control group than Opal’s
study.2 According to the study, the worldwide 28-day mortality rate of septic shock patients
was reported to be 46.9% during years 1991-1995, which is the same time frame Opal’s
confirmatory trial was conducted.2 Based on the data, we expect approximately 13% difference
to be statistically significant. Although Shakoory’s reanalysis was underpowered, the 28-day
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mortality in the intervention group was 34.6% compared to 64.7% in the placebo group,
corresponding to a 47% reduction in mortality which further supports are estimation.14
We also propose our study to be a 1-sided test as the study is designed to test the hypothesis of
reduction in mortality with intervention versus placebo, and we will not be testing the opposite
hypothesis (increase in mortality rate with intervention). This is similar to the 1-sided test
design conducted by Annane et al in determining the effect of corticosteroids in patients with
septic shock.26 90% power with 0.05 type I error was used to calculate the sample size in this
study.26

Data Analysis
Fischer and Opal’s first trial used a generalized Wilcoxon statistic to evaluate the
survival times for the three groups studied. They also used Pearson's X2 analysis, one-way
analysis of variance, or nonparametric rank comparisons using the Kruskal-Wallis Test to
stratify the three groups according to demographic and pretreatment variables.9
Opal and his colleagues used analysis of variance to test for treatment comparability of
continuous baseline measurements in the second study. 28-day mortality rates and other
categorical measurements were analyzed using Chi-square tests.8
Both prospective trials followed the intent-to-treat principle to the primary end point.
In the confirmatory study by Opal, an independent Safety and Efficacy Monitoring
Board was tasked to perform an interim analysis approximately half of the target population
had been enrolled and had completed the trial. The interim analysis was to evaluate major
safety issues or statistically significant difference in outcome as well as to evaluate the

39

probability of study end points to be met.8 Our study will utilize a similar interim analysis by an
independent review board at 1 year of study.

2.5 Conclusion
The meta-analysis by Friedman, Stevenson and Fleischmann highlighted the burden of
sepsis and sepsis mortality remains high. As we make progress in understanding the complex
physiology behind sepsis as well as the challenges in accurately staging and defining sepsis,
there is a need to make equal progress in discovering effective, targeted therapies. Although
Opal and his colleagues introduced interleukin-1 blockade in treatment of sepsis in his highly
cited study over two decades ago, anakinra wasn’t recognized as potential therapy for patients
with sepsis until the reanalysis of the original trial just recently by Shakoory et al.
As part of an effort to tackle the widespread challenge of sepsis, we propose a targeted
double blind, randomized control trial evaluating the efficacy of anakinra verses placebo to
reducing all-cause 28-day mortality in patients with septic shock, using the Sepsis-3 definition
to specifically target patients with higher mortality.

40

References:
1.
2.

3.

4.

5.

6.

7.

8.

9.

10.
11.
12.

13.

14.

Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time.
Critical care medicine. 1998;26(12):2078-2086.
Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of
mortality trends among patients with severe sepsis: a comparative meta-analysis*.
Critical care medicine. 2014;42(3):625-631.
Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of Global Incidence and
Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir
Crit Care Med. 2016;193(3):259-272.
Dinarello CA. The proinflammatory cytokines interleukin-1 and tumor necrosis factor
and treatment of the septic shock syndrome. The Journal of infectious diseases.
1991;163(6):1177-1184.
Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected
treatment strategies for septic shock based on proposed mechanisms of pathogenesis.
Ann Intern Med. 1994;120(9):771-783.
Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in
monogenic autoinflammatory diseases and implications for common illnesses. J Allergy
Clin Immunol. 2009;124(6):1141-1149; quiz 1150-1141.
Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying
therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an
international multicenter series. Arthritis and rheumatism. 2011;63(2):545-555.
Opal SM, Fisher CJ, Jr., Dhainaut JF, et al. Confirmatory interleukin-1 receptor
antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebocontrolled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator
Group. Critical care medicine. 1997;25(7):1115-1124.
Fisher CJ, Jr., Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor
antagonist in the treatment of patients with sepsis syndrome. Results from a
randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome
Study Group. Jama. 1994;271(23):1836-1843.
Jain S, Thongprayoon C, Espinosa RE, et al. Effectiveness and Safety of Anakinra for
Management of Refractory Pericarditis. Am J Cardiol. 2015;116(8):1277-1279.
Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated
with anakinra. Nature clinical practice Rheumatology. 2008;4(11):615-620.
Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful
treatment of severe paediatric rheumatic disease-associated macrophage activation
syndrome with interleukin-1 inhibition following conventional immunosuppressive
therapy: case series with 12 patients. Rheumatology (Oxford, England). 2011;50(2):417419.
Rajasekaran S, Kruse K, Kovey K, et al. Therapeutic role of anakinra, an interleukin-1
receptor antagonist, in the management of secondary hemophagocytic
lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome
in critically ill children*. Pediatr Crit Care Med. 2014;15(5):401-408.
Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 Receptor Blockade Is
Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage

41

15.
16.
17.
18.
19.
20.

21.

22.
23.

24.

25.
26.

Activation Syndrome: Reanalysis of a Prior Phase III Trial. Critical care medicine.
2016;44(2):275-281.
Martinez ML, Ferrer R, Torrents E, et al. Impact of Source Control in Patients With
Severe Sepsis and Septic Shock. Critical care medicine. 2017;45(1):11-19.
Lagunes L, Encina B, Ramirez-Estrada S. Current understanding in source control
management in septic shock patients: a review. Ann Transl Med. 2016;4(17):330.
Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ.
2016;353:i1585.
Taeb AM, Hooper MH, Marik PE. Sepsis: Current Definition, Pathophysiology,
Diagnosis, and Management. Nutr Clin Pract. 2017;32(3):296-308.
Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in
humans. Seminars in immunology. 2013;25(6):469-484.
Zapata-Tarres M, Arredondo-Garcia JL, Rivera-Luna R, et al. Interleukin-1 receptor
antagonist gene polymorphism increases susceptibility to septic shock in children with
acute lymphoblastic leukemia. Pediatr Infect Dis J. 2013;32(2):136-139.
Tolsma V, Schwebel C, Azoulay E, et al. Sepsis severe or septic shock: outcome
according to immune status and immunodeficiency profile. Chest. 2014;146(5):12051213.
Trivedi V, Bavishi C, Jean R. Impact of obesity on sepsis mortality: A systematic
review. Journal of critical care. 2015;30(3):518-524.
Lundberg JS, Perl TM, Wiblin T, et al. Septic shock: an analysis of outcomes for
patients with onset on hospital wards versus intensive care units. Critical care medicine.
1998;26(6):1020-1024.
Faine BA, Noack JM, Wong T, et al. Interhospital Transfer Delays Appropriate
Treatment for Patients With Severe Sepsis and Septic Shock: A Retrospective Cohort
Study. Critical care medicine. 2015;43(12):2589-2596.
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus
Definitions for Sepsis and Septic Shock (Sepsis-3). Jama. 2016;315(8):801-810.
Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of
hydrocortisone and fludrocortisone on mortality in patients with septic shock. Jama.
2002;288.

42

CHAPTER 3 – STUDY METHODS
3.1 Study Design
This is a placebo-controlled, randomized, double-blind study to be performed at the
adult medicine intensive care unit at Yale-New Haven Hospital(YNHH).
Randomization will be obtained using a computer-generated random number sequence that will
maintain concealed and blinded to all participants of the study including but not limited to
study subjects, pharmacists, medical providers and research analysts. We plan to randomize
patients into either the intervention(anakinra) group or the placebo group in 1:1 ratio.
The primary objective of the study will be to evaluate the efficacy of anakinra in
reduction of 28-day mortality in comparison with a placebo.

3.2 Study Population and Sampling
The study will screen all adult patients (≥18 years old) admitted to the YNHH Medical
Intensive Care Unit during the study period to determine if the patient meets the criteria for
septic shock according to the Sepsis-3 definition.1 The clinical criteria we will use to identify
patients in septic shock an increase of two or more points of the SOFA score with vasopressor
requirement to maintain a mean arterial pressure of 65mmHg or greater and serum lactate level
greater than 2 mmol/L(>18 mg/dL) in the absence of hypovolemia.
The evaluation of eligible participants will be conducted through the electronic medical
record system, EPIC by a registered nurse research analyst hired by the investigators using
flyers (Appendix F). The analyst will review patient’s medical records daily to identify patients
that meet the eligibility criteria.

43

Exclusion criteria includes advanced directives, pregnancy, scheduled operations within
28-days, and conditions that cause immunocompromise (i.e. HIV, hematologic malignancies).

3.3 Recruitment Timeline

We propose the following timeline for our study:

•By August 2017
HIC Submission

•September 2017(estimated)
HIC Approval

Patient
Recruitment

Data
Collection and
Analysis

•Start: August 2017
•End: June 2019

•Start: August 2017
•End: August 2019

Figure 5. Timeline of Planned Study
This study will be conducted over a total of 2 years, including recruitment, data
collection and analysis. Patients will be enrolled as identified for the first 22 months of study.
All recruitment of subject will end by no later than 2 months prior to the completion of the
study. Data will be collected throughout the study as patients are enrolled and the outcome
observed. Data analysis will be performed at 12 months (interim analysis) and at 22 months,
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allowing two months for data analysis at each point. (See Appendix C for proposed study flow
chart)

3.4 Subject Protection and Confidentiality

We plan to seek approval by the Human Investigation Committee (HIC) at Yale before
August 2017 as specified above. Written informed consent will be obtained from eligible
patients or their family members if patients are not able to provide consent (Appendix C).
Special considerations for special patient populations, issues regarding breach of confidentiality
and methods to ensure HIPAA compliance are all outlined in the consent form. To ensure
safety of our participants, we plan an interim analysis at the 12-month mark. An independent
safety monitoring board shall meet after at the interim analysis end point to decide whether the
study shall continue or be terminated.
All study investigators will be required to sign a Confidentiality and Non-Disclosure
Agreement Form to ensure the confidentiality of data obtained throughout the study, in
compliance with current HIPAA regulations (Appendix D).

3.5 Study variables and measures

The independent variable of this study will be the administration of anakinra. The
intervention group will receive an initial 100mg bolus of anakinra at enrollment of trial
followed by a 72-hr intravenous infusion at 2mg/kg/hr. The control group will receive normal
saline as placebo in the same manner of administration (100mg bolus + 72-hr IV infusion of
anakinra equivalent volume*). *anakinra is commonly manufactured in 100mg/0.67mL form.
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The primary dependent variable observed in this study will be 28-day, all-cause
mortality. All eligible patients will be followed over the 28-day study period after study entry
or until death, whichever occurs first.
Baseline data of the study participants will be collected at the time of enrollment by our
research coordinator. The data set will include age, sex, race, BMI, comorbidities, pathogen of
infection (if identified), SOFA score, lactate level, vital signs, and vasopressors administered.
The research analyst will require access to EPIC, the Medical Intensive Care Unit of YNHH
and workspace with computer access.

3.6 Blinding of Intervention and Outcome

The computer-generated list to randomize patients into the two arms of the study will be
concealed to all participants and investigators of the study. The pharmacy will provide unlabeled vials of either the placebo or anakinra following the sequence of the randomization list.
A confidentiality form will be signed by all pharmacists and medical staff involved in the study
to ensure blinding (Appendix C). Data analysis by the independent review board will be kept
blinded to all study participants and investigators until termination of the study.

3.7 Adherence

There are no foreseen major concerns with adherence in our study population. However,
a patient may withdraw from the study at any time for any reason as specified in the consent
form. The data from patients that withdraw from the study will be censored at the time of
withdrawal and included in the analysis.
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To ensure adherence to intervention, the research analyst will confirm the
administration of anakinra or placebo each day during the intervention period.

3.8 Monitoring of adverse events
Safety of Anakinra in human use is well documented in previous studies.2-7 We will
continuously monitor for adverse reactions including but not limited to: headache,
nausea/vomiting/diarrhea, opportunistic infection, arthralgia, fever, and cytopenia. Given that
anakinra is an immune suppressing agent and it is being administered to patients with severe
bacterial infections, care to monitor for worsening infection or a high rate of new, hospitalacquired infection will be taken.

3.9 Sample Size Calculation
To calculate our sample size, we used severe sepsis 28-day mortality of 46.9%8 reported
by Stevenson et al. in their 2014 study of severe sepsis (including septic shock) worldwide. The
expected 28-day mortality in the intervention group we used in our sample size study was
33.1% as calculated in the reanalysis of the anakinra vs. placebo phase III trial.3,9 To detect a
13.8% difference with 80% power and 0.05 alpha our predicted sample size needed was a total
of 394 patients (Appendix G).
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3.9 Analysis

The primary outcome of the study (28-day, all-cause mortality rate) will be analyzed
using Chi-square tests, which we determined to be the best method to analyze a binomial
outcome. All analyses will be conducted on an intention-to-treat basis. Patient baseline
characteristics and study variables will be stratified using multiple logistic regression to adjust
for differences that may affect outcome.
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CHAPTER 4 – CONCLUSION

The primary limitation of the proposed study may lie in its design as a single-center
trial, which complicates the generalizability of the results. The advantage of a single-centered
trial is that it helps lessen the variability that exists between individual clinician practice and
sepsis treatment protocol on from institutional level. The more controlled setting of a singlecenter, fixed care setting of the adult Medical Intensive Care Unit may provide a more uniform
standard of care compared to a multi-centered study.
Another possible limitation of the study is in its time restriction of a two-year
timeframe, potentially making it difficult for the study to reach its target sample size based on
the current incidence of septic shock. This may result in an underpowered study or the early
termination of the study during the interim analysis if the target sample size is deemed not to be
achievable.
Determining the precise timing of anakinra administration for maximum efficacy has
been a question that has been challenging to clinicians. The complexity of the inflammatory
process makes it difficult to assess when the IL-1Ra blockade will be most beneficial to the
patient. Finding the right balance between controlling a dysregulated host inflammation while
allowing the body to respond appropriately to an infection remains a challenge and may work
as an invisible confounding factor of outcome. However, we are reassured that by standardizing
the timing of the intervention, we can reduce the confounding to a lesser degree. Although each
patient may undergo a different physiological timeline of responding to sepsis and recovery
time from septic shock may vary, the prospective design of the study allows for maximum
correlation between cause and effect of the intervention planned.
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The variability between entry criteria for sepsis has been a confounding factor in many
previous studies due to the inconsistent definition of sepsis and septic shock. Following the
recommendations set by the Sepsis-3 Consensus, we were able to standardize the entry criteria
for septic shock thereby reducing the variability between patients in terms of baseline illness
severity.
Also, using a drug with an established safety profile minimizes the risk of adverse side
effects, increasing the safety for our subjects. While unforeseen side effects are difficult to
eliminate, we are hopeful there will be minimal risk of harm to our study population with the
intervention planned.
Despite novel efforts to treat sepsis and septic shock, mortality remains high and we are
still in search of a definitive therapy. Positive results from this study can lead clinical practice
in a new therapeutic approach to septic patients. Through immune modulation, our
understanding the pathophysiology of sepsis in the past years may be translated into more
effective therapy.
While the mortality rate from sepsis has been slowly declining over the years, incidence
is rising, possibly due to the aging population. Also, both the mortality rate and incidence
remain much higher in lower income countries. Devising an easily reproducible, novel therapy
may serve as a much-needed answer to the difficult question posed by septic shock, which
affects all populations worldwide.
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APPENDICES
APPENDIX A – Inclusion Criteria Reported by Opal et al. in the 1997 Phase III Trial
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APPENDIX B – Exclusion Criteria Reported by Opal et al. in the 1997 Phase III Trial
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APPENDIX C – Study Flow Chart
(#) Patients
assessed for
eligibility

excluded

eligible

Enrollment

-pregnancy
-immunocompromised
-scheduled surgery

(#)
Randomized

Randomization

Allocation

placebo + standard of
care

Follow-up

- lost to follow-up

- lost to follow-up

- discontinued treatment

- discontinued treatment

( ) included in analysis

( ) included in analysis

Analysis
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anakinra + standard of
care

APPENDIX D – Consent Form for Study Participants

CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
200 FR. 1 (2016-2)

YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL

Study Title: Reducing Mortality with Anakinra in Septic Shock

Principal Investigator: Geoffrey Connors, MD
Co-Principal Investigator: Juyeon Chung
Funding Source: (To be determined)

Invitation to Participate and Description of Project

You are invited to participate in a research study designed to look at the efficacy of using anakinra, an
interleukin-1 inhibitor in reducing mortality in patients with septic shock. You have been asked to participate because
you meet the clinical criteria defined by the Sepsis-3 definition as “septic shock”. This study will aim to recruit
approximately 400 participants admitted to the Medical Intensive Care Unit and Step-Down Unit of Yale-New
Haven Hospital between August 2017 and June 2019.

In order to decide whether or not you wish to be a part of this research study you should know enough
about its risks and benefits to make an informed decision. This consent form gives you detailed information about
the research study, which a member of the research team will discuss with you. This discussion should go over all
aspects of this research: its purpose, the procedures that will be performed, any risks of the procedures, and possible
benefits. Once you understand the study, you will be asked if you wish to participate; if so, you will be asked to sign
this form.
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Description of Procedures
▪

As a participant of this study, you will be randomized to one of two groups:

▪

The “placebo” group. This is the study “control” group.

▪

The “anakinra” group. This is the study “intervention” group.

▪

Randomization will be obtained by a computer-generated algorithm.

▪

The clinicians, researchers and participants will all be blinded to the group assignments. This
means all parties will not know which group a participant is assigned to.

▪

The “placebo” group WILL NOT receive anakinra, an anti-inflammatory agent in addition to
standard of treatment for septic shock.

▪

The “anakinra” group WILL receive anakinra in addition to standard of treatment for septic shock.

▪

For the anakinra group, 100 mg bolus of anakinra will be administered intravenously(IV) initially,
followed by a 2mg/kg/hr IV infusion for 24hrs. For the placebo group, the same amount of normal
saline will be administered. Normal saline is a non-harmful solution that is optimized to the
concentration of your blood. The amount administered will be a negligible amount to have any
significant physiological effects. It is also a part of standard of therapy for patients in septic shock.

▪

The administration of anakinra or placebo should not require additional intravenous access than
needed for standard treatment for septic shock.

▪

The total length of participation in this study is 28 days.

▪

Treatment related to this study will last 72 hours (3 days) from point of enrollment and initiation
of treatment.

▪

You will receive standard of care during the remainder of the hospitalization.

▪

This study requires reviewing of participants’ medical record for demographic information as
well as other information relevant to the study. For example, researchers of this study may collect
information that may include but not limited to: your age, gender, race, height, weight, past
medical history and medication history. This information will help researchers evaluate potential
confounders in the results of this study. For research involving review of subject’s medical record,
the consent form should explain what types of information will be collected, and why.

You will be told of any significant new findings that are developed during the course of your
participation in this study that may affect your willingness to continue to participate.
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Risks and Inconveniences
▪

There are no significant foreseeable risks, discomforts or inconveniences associated with the
study.

▪

Anakinra has been proven to be safe for use in multiple clinical trials.

▪

The most common reported side effect of anakinra is skin irritation at the injection site. Our study
will utilize intravenous administration of anakinra, therefore eliminating the side effects of skin
/tissue injection.

▪

Other possible side effects of anakinra may include but not limited to: headaches, nausea,
vomiting, diarrhea, joint pain, changes in blood cell count, or increased risk of infections.

▪

There are no documented studies showing risk of using anakinra during pregnancy. However, as
there are limited research on anakinra use in your population, please discuss with your clinician
of if you are pregnant or could be pregnant.

▪

Participation in this study may involve risks that are currently not known.

▪

There will be no genetic testing or related testing involved with this research

Benefits
▪

The goal of this study is to identify whether the use of anakinra can risk of death in septic shock
patients. Thus, if you receive the assigned treatment, we hope it may improve your survival and
outcome.

▪

Any findings derived from this study will also serve to advance scientific knowledge for medical
experts at large

Economic Considerations
▪

There are no additional medical care costs you will be subject to in association with this research.

▪

You will still be responsible for any co-pays required by your insurance company for standard
treatment.

▪

If you are assigned to receive the intervention(anakinra), it will be offered at no charge to you.

▪

Subjects may be offered an estimate of the charges they will be expected to cover.
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Treatment Alternatives/Alternatives
▪

The use of anakinra is a new approach to sepsis care and therefore no parallel alternative
treatment exists. There may be other experimental treatment to sepsis outside of this study.
Please consult your physician if you are interested in knowing what other clinical trials may
be available.

▪

You may choose to not participate in this study.

▪

Please note that alternatives are not limited to curative procedures. For chronic or terminally
ill subjects, alternatives may include procedures for symptom management, improving the
ability to function, or palliative care.

Confidentiality
▪

Study subjects’ data will be kept for a maximum of 3 years before it is destroyed or de-identified.

▪

Information about your study participation will be entered into your Electronic Medical Record
(EMR). Once placed in your EMR, these results are accessible to all of your providers who
participate in the EMR system. Information within your EMR may also be shared with others
who are appropriate to have access to your EMR (e.g. health insurance company, disability
provider.)

▪

Authorized representatives of the Food and Drug Administration (FDA) [or a funding agency,
such as the National Institutes of Health] and the manufacturer of anakinra may need to review
records of individual subjects. As a result, they may see your name; but they are bound by rules
of confidentiality not to reveal your identity to others.

▪

Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as required by U.S. or State law.
Examples of information that we are legally required to disclose include abuse of a child or elderly
person, or certain reportable diseases. [Describe the methods used to safeguard the confidentiality
of subjects’ data (e.g., coding data or samples with numbers, storing research materials in locked
cabinets, password-protecting data stored on a computer, etc.] When the results of the research
are published or discussed in conferences, no information will be included that would reveal your
identity unless your specific consent for this activity is obtained.

▪

Representatives from the Yale Human Research Protection Program, the Yale Human
Investigation Committee (the committee that reviews, approves, and monitors research on human
subjects) may inspect study records during internal auditing procedures.
individuals are required to keep all information confidential.
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However, these

In Case of Injury

▪

If you are injured while on study, seek treatment and contact the study doctor as soon as you are
able.

▪

If you become ill or are physically injured due to the study [drug/device] [provide name of
agent] or any investigational procedure specifically required by the plan for this study, you will
not be responsible for the costs required to diagnose or treat such injury. The costs of diagnosis
and medical care for any complication, injury, or illness caused by the study [drug/device] or
properly performed non-standard of care investigational procedure required by the study will be
covered by the Sponsor as long as you have followed the directions of the study doctor.

▪

If you receive a bill for any costs related to the diagnosis or treatment of your injury, please
contact the study doctor.

▪

You will not receive any other kind of payment. There are no plans to pay you for such things
as lost wages, disability, or discomfort as part of this study. You do not give up any of your
legal rights by signing this consent form.

▪

Yale School of Medicine and Yale-New Haven Hospital do not provide funds for the treatment
of research-related injury. If you are injured as a result of your participation in this study,
treatment will be provided. You or your insurance carrier will be expected to pay the costs of
this treatment. No additional financial compensation for injury or lost wages is available.

You do not give up any of your legal rights by signing this form.

Voluntary Participation and Withdrawal
Participating in this study is voluntary. You are free to choose not to take part in this study.
Refusing to participate will involve no penalty or loss of benefits to which you are otherwise entitled
(such as your health care outside the study, the payment for your health care, and your health care
benefits). However, you will not be able to enroll in this research study and will not receive study
procedures as a study participant if you do not allow use of your information as part of this study.
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Withdrawing from the Study
If you do become a subject, you are free to stop and withdraw from this study at any time during
its course. This included during or after treatment with anakinra or placebo
To withdraw from the study, you can call a member of the research team at any time and tell
them that you no longer want to take part. This will cancel any future appointments (if applicable).
The researchers may withdraw you from participating in the research if necessary. Involuntary
withdrawal may be due to development of serious side effects or early termination of the study.
Withdrawing from the study will involve no penalty or loss of benefits to which you are otherwise
entitled. It will not harm your relationship with your own doctors or with Yale-New Haven Hospital. We
would still treat you with standard therapy or, at your request, refer you to a clinic or doctor who can offer
this treatment.
When you withdraw from the study, no new health information identifying you will be gathered
after that date. Information that has already been gathered may still be used and given to others until the
end of the research study, as necessary to insure the integrity of the study and/or study oversight.

Questions
We have used some technical terms in this form. Please feel free to ask about anything you don't
understand and to consider this research and the consent form carefully – as long as you feel is necessary
– before you make a decision.
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Authorization

I have read (or someone has read to me) this form and have decided to participate in the project described
above. Its general purposes, the particulars of my involvement and possible hazards and inconveniences
have been explained to my satisfaction. My signature also indicates that I have received a copy of this
consent form.

Name of Subject:_____________________________

Signature:___________________________________
Relationship:________________________________
Date:______________________________________

___________________________________________

___________________

Signature of Principal Investigator

Date

or

_________________________________________________
Signature of Person Obtaining Consent

___________________
Date

If you have further questions about this project or if you have a research-related problem, you
may contact the Principal Investigator: Juyeon Chung, (xxx) xxx-xxxx
If, after you have signed this form you have any questions about your privacy rights, please
contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with someone other
than the researchers to discuss problems, concerns, and questions you may have concerning this
research, or to discuss your rights as a research subject, you may contact the Yale Human
Investigation Committee at (203) 785-4688.
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APPENDIX E – Non-Disclosure and Confidentiality Agreement

NON-DISCLOSURE AND CONFIDENTIALITY AGREEMENT
Research Title: Reducing Septic Shock Mortality with Anakinra

As a participant of this research I understand that I may have access to confidential
information about the study intervention and participants. By signing this statement, I am
demonstrating my understanding of my responsibilities to maintain confidentiality and agree to
the following:

▪

I understand that any identifying information about study sites and participants are
completely confidential.

▪

I agree not to divulge, publish, or otherwise make known to unauthorized persons or to
the public any information obtained in the course of this research project that could
identify the persons who participated in the study.

▪

I understand that all information about study sites or participants obtained or accessed
by me in the course of my work is confidential. I agree not to divulge or otherwise make
known to unauthorized persons any of this information, unless specifically authorized to
do so by approved protocol or by the local principal investigator acting in response to
applicable law or court order, or public health or clinical need.

▪

I understand that I am not to read information about study sites or participants, or any
other confidential documents, nor ask questions of study participants for my own
personal information but only to the extent and for the purpose of performing my
assigned duties on this research project.

▪

I agree to notify the local principal investigator immediately should I become aware of an
actual breach of confidentiality or a situation which could potentially result in a breach,
whether this be on my part or on the part of another person.

______________________________
Signature

________________ _____________________
Date
Printed name

______________________________ ________________ _____________________
Signature of local principal investigator Date
Printed name
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APPENDIX F – Research Analyst Recruitment Flyer

RESEARCH STUDY
Would you like to participate in clinical research?
We are looking for part-time or full-time research assistants to aid in the study of
evaluating the efficacy of a new therapy for patients with septic shock.
This is a paid position. Please contact the number below for information on compensation.

Eligibility: Registered Nurse or equivalent level medical-degree.
Responsibilities:
-Dedicate 8-40hr/wk depending on full- or part-time participation
-Review patient records on EPIC while complying to HIPAA(training is required)
-Screen and interview potential study subjects in the Medical Intensive Care Unit at YNHH

For questions or if you are interested in participating in this study, please contact the primary
investigator:
Juyeon Chung at (xxx)xxx-xxxx or email at juyeon.chung@yale.edu
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APPENDIX G – Sample Size Calculation

Estimated
control group
mortality rate*:
46.9%

Alpha level: 0.05

Estimated
intervention
group mortality
rate: 33.1%

Study power:
80%

1:1 group
assignment ratio

Beta: 0.2

Calculated
sample size:
total 394
patients

*28-day, all-cause mortality
**Sample size calculator was derived from http://clincalc.com/stats/samplesize.aspx. Rosner B. Fundamentals
of Biostatistics. 7th ed. Boston, MA: Brooks/Cole; 2011.
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